Infectious disease exposure due to the use of plasma-derived FVIII products in addition to possible shortages in plasma donations, as recently experienced during the COVID-19 pandemic [25,26,27], motivated the development of recombinant FVIII (rFVIII) products, which now dominate FVIII replacement therapy. Here, F8 is linked to infectious disease.